Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $196.75 Consensus Target Price from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received a consensus rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $196.75.

Several analysts have recently commented on the company. Citigroup restated a “neutral” rating and issued a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. Chardan Capital raised their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Evercore ISI boosted their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, HC Wainwright boosted their price objective on Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $177.14 on Monday. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The stock has a 50 day simple moving average of $192.47 and a two-hundred day simple moving average of $179.64. The company has a market cap of $5.06 billion, a P/E ratio of 94.73 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. Krystal Biotech’s quarterly revenue was up 70283900.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.25) EPS. On average, research analysts predict that Krystal Biotech will post 3.13 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its position in Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after buying an additional 231,255 shares during the last quarter. Eventide Asset Management LLC purchased a new stake in Krystal Biotech in the 4th quarter worth about $16,932,000. Braidwell LP raised its stake in Krystal Biotech by 153.2% in the 4th quarter. Braidwell LP now owns 196,200 shares of the company’s stock valued at $24,341,000 after acquiring an additional 118,703 shares during the period. Principal Financial Group Inc. raised its stake in Krystal Biotech by 1,972.0% in the 2nd quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock valued at $22,674,000 after acquiring an additional 117,510 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Krystal Biotech by 115.7% during the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after purchasing an additional 103,928 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).